$5.42
0.00% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US8269171067
Symbol
SIGA

SIGA Technologies Inc Stock price

$5.42
-0.92 14.51% 1M
-3.91 41.91% 6M
-0.59 9.82% YTD
+0.42 8.35% 1Y
+0.57 11.71% 3Y
+1.68 44.76% 5Y
+3.58 195.26% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.09 1.63%
ISIN
US8269171067
Symbol
SIGA

Key metrics

Market capitalization $387.01m
Enterprise Value $289.28m
P/E (TTM) P/E ratio 4.50
EV/FCF (TTM) EV/FCF 4.05
EV/Sales (TTM) EV/Sales 1.67
P/S ratio (TTM) P/S ratio 2.23
P/B ratio (TTM) P/B ratio 2.28
Dividend yield 0.00%
Last dividend (FY23) $0.42
Revenue growth (TTM) Revenue growth 399.31%
Revenue (TTM) Revenue $173.73m
EBIT (operating result TTM) EBIT $104.57m
Free Cash Flow (TTM) Free Cash Flow $71.46m
Cash position $99.27m
EPS (TTM) EPS $1.20
P/E forward 5.16
P/S forward 2.42
EV/Sales forward 1.81
Short interest 9.83%
Show more

Is SIGA Technologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

SIGA Technologies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast SIGA Technologies Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast SIGA Technologies Inc:

Buy
100%

Financial data from SIGA Technologies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
174 174
399% 399%
100%
- Direct Costs 32 32
719% 719%
18%
142 142
359% 359%
82%
- Selling and Administrative Expenses 25 25
25% 25%
14%
- Research and Development Expense 12 12
43% 43%
7%
105 105
1,227% 1,227%
61%
- Depreciation and Amortization 0.55 0.55
4% 4%
0%
EBIT (Operating Income) EBIT 105 105
1,161% 1,161%
60%
Net Profit 86 86
1,814% 1,814%
49%

In millions USD.

Don't miss a Thing! We will send you all news about SIGA Technologies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SIGA Technologies Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as TPOXX in the United States, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric p...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA's tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in ti...
Negative
Seeking Alpha
3 months ago
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential po...
More SIGA Technologies Inc News

Company Profile

SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Head office United States
CEO Diem Nguyen
Employees 45
Founded 1995
Website www.siga.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today